Charles Schwab Investment Management Inc. Sells 37,764 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Charles Schwab Investment Management Inc. lowered its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 6.3% in the 4th quarter, HoldingsChannel reports. The fund owned 558,446 shares of the biopharmaceutical company’s stock after selling 37,764 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Vanda Pharmaceuticals were worth $2,675,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC raised its position in shares of Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 5,459 shares during the period. JPMorgan Chase & Co. grew its stake in Vanda Pharmaceuticals by 16.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company’s stock valued at $754,000 after buying an additional 22,249 shares in the last quarter. Franklin Resources Inc. grew its stake in Vanda Pharmaceuticals by 8.8% in the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 4,449 shares in the last quarter. Barclays PLC raised its holdings in Vanda Pharmaceuticals by 128.2% during the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 86,677 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 7.1% during the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock worth $6,689,000 after acquiring an additional 94,870 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the stock in a transaction dated Friday, February 28th. The shares were purchased at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the transaction, the chief executive officer now owns 2,361,730 shares in the company, valued at $11,241,834.80. This represents a 0.43 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders acquired 32,000 shares of company stock worth $151,180. 8.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

VNDA has been the subject of several recent research reports. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright lifted their target price on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, February 18th.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $4.60 on Friday. The firm has a fifty day moving average price of $4.66 and a two-hundred day moving average price of $4.75. The company has a market cap of $268.25 million, a price-to-earnings ratio of -14.38 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a one year low of $3.87 and a one year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Equities research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.